BridgeBio Pharma, Inc. (BBIO) Revenue by Segment
BridgeBio Pharma revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), BridgeBio Pharma's largest product or service was Product, with $222.44 million or 91% of revenue, up 211.1% from a year earlier. Next: Royalty (6%) and License and Service (2%).
The fastest-growing product or service from a year earlier was Royalty (+850.2%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2020.
BridgeBio Pharma, Inc.
BBIO
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
BridgeBio Pharma revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Product | $222.4M | $180.6M | $108.1M | $71.5M | 91% |
| Royalty | $15.4M | $9.5M | $4.3M | $1.6M | 6% |
| License and Service | $5.8M | $4.4M | $8.3M | $37.4M | 2% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for BridgeBio Pharma?
Product: $222.44 million, or 91% of revenue, in Q2 fiscal 2026.
What are BridgeBio Pharma's main products and services?
By revenue in Q2 fiscal 2026: Product (91%), Royalty (6%) and License and Service (2%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
